FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do

A US FDA advisory committee recommended allowing six popular, unapproved peptides to be used by compounding pharmacies, despite regulator concerns over lack of clinical data. While advisory, the vote signals a potential legitimisation of the 'grey market' for these substances, pending a final FDA decision.

This Wire brief sits within Fusion42's coverage of Longevity & Wellness. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.